A combination of pembrolizumab and low-dose ipilimumab appears to be active and to have a better safety profile than a combination of nivolumab and full-dose ipilimumab in advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Conferences
Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma
Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist) versus vemurafenib (Zelboraf) plus cobimetinib (Cotellic).
Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab Combination
Tara C. Gangadhar, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.
Epacadostat, an IDO inhibitor, and pembrolizumab, a PD-1 blockade, were tested in combination in patients with various advanced cancers to evaluate the safety of the drugs together.
Pembrolizumab Induces Responses in Melanoma Patients With Brain Mets
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases. The data were presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.